were introduced in in vitro fertilization (IVF) protocols to prevent endogenous luteinizing hormone (LH) surge
erstimulation (COH) over the last decade. First, they
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versely, other investigators tried to take advantage of

Methods: The gonadotroph (FSH, LH) and steroid [estradiol the initial endogenous gonadotropin flare induced by (E 2 ) and progesterone (P)] flare-up was studied on two
agonists to improve follicular recruitment in the so- hand, it is still unclear whether such a reduction in
Treatment Protocol
were switched in the second cycle according to a crossing over design. GnRH-a dose may adversely affect the hypophyseal A progestogen pretreatment (norethisterone; Norluand ovarian hormonal secretion during the flare-up ten; Smith-Kline-French, Nanterre, France: 10mg/day period.
for 10-15 days starting at mid-cycle) is currently used Thus, the purpose of this study was to prospectively in our unit in order to program IVF cycles and to avoid compare the endogenous gonadotropin (FSH, LH) and oocyte retrieval during the weekend. As progestogens steroid (estradiol and progesterone) responses are known to modify the hormonal response to GnRH observed following administration of a standard dose agonist (12), a similar administration of progestogen (100 g) or a low dose (25 g) of triptorelin in normowas performed in both cycles before administration of ovulatory women.
the agonist. Blood samples were obtained every morning before each injection of triptorelin from Day 1 to Day 3
MATERIALS AND METHODS
of the cycle and were kept frozen until subsequent determination of plasma FSH, LH, estradiol, and progesterone levels. Patients
Thirty patients entering an IVF program for tubal
Hormonal Assays disease, male factor, endometriosis, or unexplained infertility were included in this study. The mean age Radioimmuno-assays were used to measure serum was 33.3 Ϯ 4.5 years (range 25-38 years). All women estradiol and progesterone (Coatria, Biomerieux, Lyon, had regular and ovulatory cycles with basal serum FSH France). The lower limit of sensitivity was 7 pg/ml for level within the normal range for our laboratory (Ͻ12 the estradiol assay and 0.05 ng/ml for the progesterone mUI/ml on Day 3). Thus, they were considered as assay. The interassay coefficients or variation (CV normoresponders. max) were 12 and 8.5%, respectively. Interassay variFor each patient, the hormonal flare-up was evaluabilities were 16 and 11%, respectively. ated following subcutaneous administration of triptore-FSH and LH were measured by enzyme immunoaslin (Decapeptyl; Ipsen-Biotech, Paris, France) at two say (MEIA, Abott, Rungis, France). The FSH assay separate doses (25 and 100 g/day) in two consecutive had an intra-and interassay CV max of 6% with a cycles (Fig. 1) . The first flare-up resulted from agonist minimum detectable value of 0.37 IU/ml. The LH injection during the first 3 days of the cycle preliminary assay had an intra-and interassay CV max of 8% with to IVF while the second one was studied in the early a minimum detectable value of 0.5 IU/ml. follicular phase of a short-term IVF protocol with agonist administration being maintained until hCG adminStatistical Analysis istration.
Patients were randomized to receive either 25 g FSH, LH, estradiol, and progesterone values were or 100g of triptorelin in the first cycle and doses analyzed by a paired Student t test. A P value Ͻ 0.05 was considered significant. Results are expressed as mean Ϯ SEM.
RESULTS
Cycle to Cycle Individual Variability
Serum LH and FSH values on Day 1 were similar in both cycles. A slight but significant difference between E 2 values was observed on Day 1 of two cycles (24.2 Ϯ 1.9 pg/ml vs. 19.9 Ϯ 2 pg/ml, P Ͻ 0.05). This may be related to intercycle variability in gen pretreatment.
Endogenous Gonadotropin Release
increases (⌬ LH/basal LH) are 492 Ϯ 70% vs. 285 Ϯ 40%, respectively (P Ͻ 0.005) (Fig. 2b) . Conversely, The peak serum values of LH and FSH were con-FSH release was not significantly different following stantly observed on Day 2. As shown on Fig. 2b , LH administration of both dosages (maximal FSH values release was significantly higher following administraare 12.3 Ϯ 2.4 mUI/ml vs 15.2 Ϯ 2 mUI/ml and tion of 100 g of Triptorelin than after injection of 25 ⌬FSH / basal FSH 100 Ϯ 15% vs. 119 Ϯ 20% after g; maximal values for LH are 22 Ϯ 2 mUI/ml vs 100 g and 25 g injection, respectively) (Fig. 2a) . 16 .3 Ϯ 1.6 mUI/ml (P Ͻ 0.005) and relative maximal
Ovarian Response
Maximum E 2 concentrations were observed on Day 2 (24 hr after the first GnRH-a injection) in about 80% of cycles. The ovarian response assessed by serum E 2 increments was not significantly different following administration of a standard or a low dose of triptorelin (E 2 maximal serum value, 38 Ϯ 9pg/ml vs. 48 Ϯ 15pg/ ml and ⌬E 2 /basal E 2 , 113 Ϯ 28% vs. 115 Ϯ 21% after 100 g and 25 g respectively) (Fig. 2c) .
Progesterone values were below 0.9 ng/ml in all samples. No significant rise was observed following triptorelin administration whatever the dose of GnRHa used (data not shown).
DISCUSSION
In a normal menstrual cycle, initiation of follicular growth is strongly dependent on FSH secretion. Similarly, the gonadotropin flare-up induced by GnRH-a administration at the early follicular phase of shortterm GnRH-a protocols participates in the follicular recruitment. It was recently suggested that diminishing the doses of GnRH agonists in IVF programs could be relevant to reducing the potential adverse effects of GnRH-a on ovarian parameters (2,3) and thus to improve ovarian responsiveness to exogenous gonadotropins. Such a reduction in GnRH-a doses proved to be helpful for poor responders treated with long-or short-term GnRH-a protocols (4-8). The improvement in ovarian response was attributed to a lower negative effect of the agonist at the ovarian level but it remains to assess whether low doses of GnRH-a may quantitatively and qualitatively modify the hormonal flare-up of the agonist.
In our study, we observed in all patients a significant increase in serum levels of both gonadotropins within 24 hr following the first administration of the GnRHa, whatever the dose used. This observation is in good This observation may be relevant specially for women release. Our results show that, in contrast with the dose-dependent LH response to GnRH-a, FSH release whose poor ovarian response has been related to a potential negative effect of GnRH agonist at the ovarfollowing administration of each dose was similar. These observations that an optimal FSH secretion ian level. Other studies are needed to confirm these observations by measuring clinical endpoints. could be achieved with a low dose of triptorelin, may be clinically relevant for short-term IVF protocols.
As far as LH secretion is concerned, previous study in nonhuman primates indicated a GnRH-a dose-REFERENCES dependent increase of serum LH (16) and our data are in line with this report. However, the actual role of 
